SYNCAR-001

SYNCAR-001 is an autologous CD19-targeting chimeric antigen receptor T cell (CAR-T) therapy that expresses an engineered interleukin-2 (IL-2) receptor, allowing it to selectively respond to STK-009, an engineered pegylated IL-2 cytokine. This two-component regimen—referred to as SYNCAR-001 + STK-009—is designed using Synthekine’s proprietary orthogonal IL-2 technology. The combination enables targeted activation and expansion of the CAR-T cells in vivo without the need for lymphodepleting chemotherapy. It is being developed primarily for autoimmune diseases such as systemic lupus erythematosus (SLE), lupus nephritis (LN), and also evaluated in B-cell malignancies including non-Hodgkin lymphoma and other CD19-positive hematologic cancers. Early clinical data show a favorable safety profile with durable responses in treated patients[1][3][4][5].

Other names

SYNCAR 001SYNCAR001SYNCAR-001